KEYVIBE-001
Phase 1 Completed
474 enrolled 39 charts
MK-4830-001
Phase 1 Completed
470 enrolled
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
68 enrolled 27 charts
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1 Completed
829 enrolled 100 charts
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Completed
851 enrolled
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Completed
304 enrolled
CANFOUR
Phase 1/2 Completed
167 enrolled
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
240 enrolled
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Phase 1 Completed
60 enrolled 15 charts
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Phase 1/2 Completed
24 enrolled
DENALI
Phase 2 Completed
82 enrolled 10 charts
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Phase 1 Completed
167 enrolled
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Phase 1 Completed
65 enrolled 32 charts
Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer
Phase 3 Completed
71 enrolled
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Phase 1 Completed
20 enrolled 14 charts
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
Phase 1 Completed
169 enrolled
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
Phase 2 Completed
80 enrolled 7 charts
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
Phase 2 Completed
50 enrolled
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Completed
43 enrolled 21 charts
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Phase 2 Completed
42 enrolled 8 charts
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Phase 2 Completed
123 enrolled 9 charts
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Phase 1 Completed
53 enrolled 15 charts
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Phase 1 Completed
102 enrolled 48 charts
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
Phase 2 Completed
124 enrolled
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Phase 1 Completed
12 enrolled 18 charts
Study of TRC102 in Combination With Pemetrexed in Cancer Patients
Phase 1 Completed
28 enrolled
Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)
Phase 3 Completed
320 enrolled
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Phase 2 Completed
27 enrolled 10 charts
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
Comparing 3 Schedules of Alimta Plus Gemzar
Phase 2 Completed
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Phase 3 Completed